#Italy #Milan #Tethis S.p.A. #Enea TECH #Biomedical Foundation

Enea TECH Invests €15 Million in Tethis for the Future of Cancer Diagnostics

In a significant move for cancer detection and treatment, Enea TECH, in partnership with the Biomedical Foundation, has announced a groundbreaking investment of €15 million in the Milan-based company Tethis S.p.A. This funding marks a commitment to advancing cancer diagnostics through innovative technologies, particularly in the emerging field of liquid biopsy.

Liquid biopsy is revolutionizing how oncologists diagnose and monitor cancer. Unlike traditional methods that often require invasive procedures, liquid biopsy utilizes a simple blood test to identify traces of tumor cells circulating in the bloodstream. Tethis is at the forefront of this innovation, developing a comprehensive analytical platform designed to enhance the precision and effectiveness of cancer diagnostics.

A Closer Look at Tethis' Technology

The cornerstone of Tethis' approach is the integration of several advanced technologies. Central to their innovation is the See.d® blood sample preparation instrument, which automates the initial steps of the liquid biopsy process. By ensuring the integrity of the blood sample at the point of collection, this tool is crucial for obtaining reliable results.

Additionally, Tethis employs SmartBioSurface® slides, treated with biocompatible nanomaterials that promote efficient adhesion of non-adherent cells. This enables in-depth analysis of proteins, RNA, and DNA at the single cell level. The slides facilitate advanced imaging techniques using artificial intelligence, allowing for the detection and characterization of rare cancer and immune cells.

The integration of cellular analysis with molecular markers presents a multi-faceted view of a patient’s oncological landscape. This means oncologists can not only diagnose the presence of cancer more accurately but also monitor changes in the disease over time, leading to better-informed treatment decisions.

The Vision Behind the Investment

According to Holger Neecke, CEO of Tethis, the investment is poised to accelerate the development and commercialization of their diagnostic technologies. “Starting with a simple blood draw, we aim to provide oncologists with comprehensive cellular and molecular analyses that advance precision diagnostics, enabling targeted therapeutic development,” he stated.

Maria Cristina Porta, General Manager of Enea TECH and the Biomedical Foundation, emphasized the pivotal role of Italy in pioneering advanced medical technologies. “Supporting revolutionary technological solutions, such as liquid biopsy, is essential for building a future with faster, more accurate, and less invasive diagnostic methods,” she remarked. Porto envisioned that these advancements could significantly enhance the quality of life for cancer patients, enabling a more personalized and effective approach to cancer care.

Previous Investments and Future Plans

This funding round is the latest development in Tethis' growth trajectory, following prior investments from firms like Genextra and Indaco Venture Partners. Together, these efforts have been instrumental in bringing Tethis' vision closer to fruition.

The continued support and investment in technologies like Tethis not only promise improvements in treatment outcomes but also pave the way for innovations that revolutionize cancer diagnostics. As the healthcare landscape evolves, strategic partnerships that focus on precision medicine will play a critical role in meeting the complex challenges presented by cancer.

For further updates on Tethis’ ongoing developments and innovative solutions in cancer care, check out Tethis Lab.

Conclusion

The partnership between Enea TECH and the Biomedical Foundation in investing in Tethis embodies a proactive approach to tackling one of healthcare's most significant challenges—cancer. With promising technologies in liquid biopsy, the future looks bright for cancer diagnosis and management, potentially transforming the lives of countless patients across the globe.